Abstracts tagged "Biomarkers"

Abstract Number: 1016 • 2016 ACR/ARHP Annual Meeting
Soluble BAT-3: A New Biomarker for Antisynthetase Syndrome
Baptiste Hervier^1,2, Samra Ouaras², Laurent Gilardin³, Hanane Ouakrim⁴, Damien Amelin⁵, Fleur Cohen⁶, Yurdagul Uzunhan⁷, Yves Allenbach¹, Anne Bourgarit-Durand⁸, Olivier Benveniste⁹ and Vincent Vieillard¹⁰, ¹Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ²CIMI Paris, UMR-S 1135, INSERM & UPMC, Paris, France, ³Internal Medicine, APHP, Hôpital Pitié Salpêtrière, Paris, France, ⁴INSERM UMR-S 1138, Centre des cordeliers & APHP, Cochin Hospital, Laboratory of Pathology, Paris, France, ⁵Sorbonne Universités UPMC Univ Paris 06, Myology research center, INSERM UMRS974, CNRS FRE3617, Pitié-Salpêtrière University Hospital, Paris, France, Paris, France, ⁶Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ⁷Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ⁸CHU Bondy, Bondy, France, ⁹Pitié-Salpêtrière University Hospital, Paris, France, ¹⁰P&M Curie university, INSERM 543, Paris, France
Background/Purpose: Antisynthetase syndrome (ARS) is an inflammatory myopathy (IM) commonly associated to interstitial lung disease (ILD) and different anti-tRNA-synthetase autoantibodies. The immune mechanisms leading to…
Abstract Number: 1665 • 2016 ACR/ARHP Annual Meeting
Validation of Germ Line Epigenetic Variants Associated with Psoriatic Disease
Remy Pollock¹, Laila Zaman¹, Vinod Chandran² and Dafna D Gladman³, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: Heritable epigenetic phenomena may play a role in the parent-of-origin effect observed in psoriasis and psoriatic arthritis (PsA). A previous epigenome-wide association study (EWAS)…
Abstract Number: 2371 • 2016 ACR/ARHP Annual Meeting
Effect of Etanercept on Several Soluble Biomarkers in a Randomized Controlled Trial of Patients with Erosive Hand Osteoarthritis
Féline Kroon¹, Ruth Wittoek², Wing-Yee Kwok¹, Klaus Bobacz³, Dirk Elewaut², Marta Favero⁴, Tom Huizinga⁵, Josef Smolen³, Bert Vander Cruyssen², Ron Wolterbeek⁶, Leonardo Punzi⁷, Gust Verbruggen², Margreet Kloppenburg⁸ and Roberta Ramonda⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Ghent University Hospital, Ghent, Belgium, ³Internal Medicine III, Div. of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Rheumatology Unit,Department of Medicine–DIMED, University of Padova, Rheumatology Unit,University of Padova, Padova, Italy, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, Netherlands, ⁷Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy, ⁸Rheumatology and Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Erosive hand osteoarthritis (OA) is a hand OA subset with high disease burden, although effective therapies are still lacking and clinical trials are scarce.…
Abstract Number: 2636 • 2016 ACR/ARHP Annual Meeting
No Strong Evidence Supporting Predictors for Successful Dose Reduction or Discontinuation of a Biologic in Rheumatoid Arthritis: A Systematic Review
L. Tweehuysen¹, C.H. van den Ende², F.M.M. Beeren², E.M.J. Been², F.H.J. van den Hoogen^3,4 and A.A. den Broeder³, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ³Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Rheumatology, Radboudumc, Nijmegen, Netherlands
Background/Purpose: Tapering of biologics in rheumatoid arthritis (RA) is based on a trial-and-error disease activity guided strategy, because it is not known in advance which…
Abstract Number: 3151 • 2016 ACR/ARHP Annual Meeting
The Diagnostic and Predictive Value of Anti-Acetylated Peptide Antibodies in RA Patients Starting Methotrexate Treatment
Paul Studenic¹, Stephan Blüml², Holger Bang³, Manuel Unger⁴, Karim Raza⁵, Daniel Aletaha⁶, Josef S. Smolen^7,8 and Günter Steiner⁹, ¹Department of Internal Medicine 3, Division of Rheumatology and Geriatric Medicine, Medical University Vienna, Vienna, Austria, ²Internal Medicine 3; Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Rsearch & Development, Orgentec Diagnostika GmbH, Mainz, Germany, ⁴Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁵University of Birmingham, Rheumatology Research Group, Institute of Inflammation and Ageing, United Kingdom, Birmingham, United Kingdom, ⁶Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁷2nd Department of Medicine, Hietzing Hospital, Vienna, Austria, ⁸Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁹Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: Anti-acetylated-peptide antibodies (AAPA) have recently been described in rheumatoid arthritis (RA) patients and may be used as a further diagnostic marker in patients with…
Abstract Number: 539 • 2015 ACR/ARHP Annual Meeting
Quantification of T-Cell Receptor Excision Circles (TREC) from Peripheral Blood in Patients with Inflammatory Polyarthritis of Recent Onset (EPA): Association with Radiographic Joint Damage
Alexandre Osborne¹, Nathalie Carrier², Artur J de Brum-Fernandes³, Patrick Liang³, Ariel Masetto⁴ and Gilles Boire³, ¹Clinical Sciences Program, Université de Sherbrooke, Sherbrooke, QC, Canada, ²Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ³Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Patients with established Rheumatoid arthritis (RA) present evidence for an exhausted immune system. It is not known whether patients seen at the Early inflammatory…
Abstract Number: 821 • 2015 ACR/ARHP Annual Meeting
Elevated Serum Levels of Soluble CD146 in Patients with Systemic Sclerosis
Kazunori Kato¹, Tomoko Ito², Naoto Tamura², Sayuri Okuda¹, Masakazu Matsushita², Kurisu Tada², Ken Yamaji² and Yoshinari Takasaki², ¹Department of Biomedical Engineering, Toyo University, Saitama, Japan, ²Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: CD146 is a transmembrane glycoprotein belonging to Ig-superfamily. Human endothelial cells, activated fibroblasts and Th17 cells express CD146 that involved in angiogenesis, fibrosis and…
Abstract Number: 1375 • 2015 ACR/ARHP Annual Meeting
S100A8/A9, a Serum and Imaging Biomarker for Assessing Joint Inflammation and Destruction in Experimental Seronegative Arthritis
Edwin J. W. Geven¹, Shahla Abdolahi-Roodsaz¹, Annet Sloetjes¹, Marije I. Koenders¹, Dirk Föll², Johannes Roth³, Thomas Vogl³ and Peter L. E. M. van Lent¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Department of Pediatric Rheumatology and Immunology, University of Münster, Münster, Germany, ³Institute of Immunology, University of Münster, Münster, Germany
Background/Purpose: Seronegative joint diseases such as psoriatic arthritis and juvenile idiopathic arthritis are characterized by the lack of autoantibodies, potent biomarkers used for predicting disease…
Abstract Number: 1850 • 2015 ACR/ARHP Annual Meeting
Increased Levels of Immunoglobulin Binding Protein 1 Are Associated with Disease Activity Including Renal Damage in Patients with Systemic Lupus Erythematosus
Eun-Ju Lee^1,2, Seokchan Hong³, Doo-Ho Lim¹, Yong-Gil Kim¹, Chang-Keun Lee¹ and Bin Yoo¹, ¹Division of Rheumatology, Department of Internal Medicine, Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ²Asan Institute for Life Science, Asan Medical Center, Seoul, South Korea, ³Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Background/Purpose: Systemic lupus erythematous (SLE) is a multisystem autoimmune inflammatory disease. Lupus nephritis (LN) is one of the most serious complications in patients with SLE.…
Abstract Number: 2446 • 2015 ACR/ARHP Annual Meeting
Synovial Fluid Proteins Differentiate Patients with Oligoarticular Juvenile Idiopathic Arthritis Who Are Destined to Extend from Those Who Will Remain Persistent in Course
AnneMarie C. Brescia¹, Megan M. Simonds², Kathleen E. Sullivan³ and Carlos D. Rose⁴, ¹Pediatric Rheumatology, Nemours A.I. duPont Hospital for Children, Wilmington, DE, ²Nemours Research, Nemours/AI duPont Hospital for Children, Wilmington, DE, ³Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Pediatrics, Nemours A.I. duPont Hospital for Children, Division of Pediatric Rheumatology, Thomas Jefferson University, Wilmington, DE
Background/Purpose: Children with oligoarticular juvenile idiopathic arthritis (JIA) who have an extended course (recruitment of 5 or more joints after 6 months of disease) have…
Abstract Number: 2803 • 2015 ACR/ARHP Annual Meeting
Systemic Interferon Type I and Type II Signatures Present in Distinct Subsets of Primary Sjögren’s Syndrome: En Route Towards More Selective Targeting
Naomi I Maria¹, Cornelia G. van Helden-Meeuwsen¹, Eline C. Steenwijk¹, Arne S. IJpma², Zana Brkic¹, Paul L. van Daele^1,3, P. Martin van Hagen^1,3, Peter J. van der Spek², Hemmo A. Drexhage¹, Wan-Fai Ng⁴ and Marjan A. Versnel¹, ¹Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ²Bioinformatics, Erasmus Medical Center, Rotterdam, Netherlands, ³Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease with a large heterogeneity in clinical phenotype. The IFN type I signature is present in…
Abstract Number: 3256 • 2015 ACR/ARHP Annual Meeting
Epigenetic Chromosome Conformations Predict MTX Responsiveness in Early Rheumatoid Arthritis Patients
Claudio Carini¹, Aroul Ramadass², Philip Jordan², Ewan Hunter², Alexandre Akoulitchev², Iain. B. McInnes³, Carl. S. Goodyear³ and Scottish Early Rheumatoid Arthritis Inception Cohort Investigators, ¹35 Cambridgepark Drive, Pfizer, Cambridge, MA, ²Oxford Biodynamics, Oxford, United Kingdom, ³Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: In early rheumatoid arthritis (RA), it is not possible to predict response to first line DMARDs (e.g. methotrexate (MTX)) and as such treatment decisions…
Abstract Number: 92 • 2015 ACR/ARHP Annual Meeting
Variation at Interleukin-6 Receptor Gene Is Associated to Joint Damage in Rheumatoid Arthritis
María López-Lasanta¹, Antonio Julià¹, Joan Maymo², Benjamin Fernandez Gutierrez³, Inmaculada Ureña⁴, Francisco J. Blanco⁵, Juan D. Cañete⁶, Mercedes Alperi-López⁷, Alejandro Olivé⁸, Hector Corominas⁹, Jesús Tornero¹⁰, Alba Erra¹¹, Miriam Almirall¹², Nuria Palau¹³, Ana M. Ortiz Garcia¹⁴, Gabriela Avila¹³, Luis Rodriguez-Rodriguez¹⁵, Arnald Alonso¹, Raül Tortosa¹, Isidoro González-Alvaro¹⁶ and Sara Marsal¹, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology, Hospital del Mar, Barcelona, Spain, ³Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁴Rheumatology service, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁵Osteoarticular and Aging Research Lab, INIBIC–Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Arthritis Unit. Rheumatology, Arthritis Unit. Rheumatology Department. Hospital Clínic, Barcelona, Spain, ⁷Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, ⁸Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁹Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ¹⁰Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ¹¹Rheumatology, Rheumatology Hospital San Rafael, Barcelona, Spain, ¹²Rheumatology Department, Hospital del Mar, Barcelona, Spain, ¹³Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ¹⁴Rheumatology, H.U. La Princesa, Madrid, Spain, ¹⁵Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ¹⁶Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain
Background/Purpose: Interleukin-6 (IL-6) cytokine signaling is key in Rheumatoid Arthritis (RA) pathophysiology. Blocking IL-6 receptor (IL6R) has proven to be a highly effective treatment to prevent joint…
Abstract Number: 545 • 2015 ACR/ARHP Annual Meeting
Baseline Serum Soluble Interleukin–2 Receptor Alpha (sIL–2Rα) Levels Increased as Intervals Decreased from Cohort Entry to Onset of Incident Rheumatoid Arthritis (pre–RA), not Observed in Matched Control (CN) Subjects
Alfonse T. Masi¹, Azeem A. Rehman¹, Jean C. Aldag¹ and Huaping Wang², ¹Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, ²Pediatrics, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Baseline sIL-2Rα levels predicted total mortality in both pre-RA and matched CN subjects, in a preceding prospective cohort study (A&R 2010; 62:S19). Now, the…
Abstract Number: 847 • 2015 ACR/ARHP Annual Meeting
Troponin T and NT-Probnp Are Prognostic Cardiac Disease Biomarkers in Patients with Systemic Sclerosis without Pulmonary Arterial Hypertension
Silvia Laura Bosello¹, Giacomo De Luca¹, Franca Forni², Clara Di Mario³, Federico parisi¹, Giovanni Canestrari¹, Giorgia Berardi¹, Manuela Rucco¹, Francesca Gabrielli⁴, Leonarda Galiuto⁴, Francesco Loperfido⁴ and Gianfranco Ferraccioli¹, ¹Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ²Department of Laboratory Medicine, Catholic University of the Sacred Heart, Rome, Italy, ³Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ⁴Division of Heart Failure and Cardiac Rehabilitation, Catholic University - Rome, Rome, Italy
Background/Purpose: Heart involvement is common in Systemic Sclerosis (SSc), even if often clinically silent, and represents one of the leading cause of death in these…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].